Pegasus' DermADAPT dressing:
This article was originally published in Clinica
Executive Summary
Advanced biologic scaffolds maker Pegasus Biologics has entered the wound care market, after receiving US FDA 510(k) market clearance for its collagen-based DermADAPT biomatrix dressing. Approved for the local management of moderate to heavy exuding wounds, the product will be initially targeted to the diabetic foot ulcer market; in the US alone, five million diabetic patients suffer from foot ulcers, according to the privately held, Irvine, California firm. DermADAPT is strong and stable, maintaining an ideal environment for wound healing, said the company. It is also thin and pliable, and conforms well to the wound bed. Pegasus already sells a product for repairing ligaments and tendons, OrthADAPT bioimplant.